Introduction
============

Nocturnal frontal lobe epilepsy (NFLE) is characterized by frequent, sometimes violent, and often brief seizures at night, that usually commence during childhood. It can arise sporadically or be inherited in an autosomal dominant fashion (ADNFLE).[@b1] Clinical features associated with nocturnal seizures include vocalizations, complex and often violent automatisms, and ambulation, making the condition sometimes difficult to distinguish from parasomnias.[@b2] Electroencephalography (EEG) is often unrevealing, and magnetic resonance imaging (MRI) typically shows no lesions in patients with NFLE. In some cases NFLE is accompanied by intellectual disability and psychiatric disorders, the pathogenic mechanisms of which remain unclear.[@b2]--[@b4]

A minority of ADNFLE cases are due to mutations in three genes (*CHRNA2*, *CHRNA4* and *CHRNB2*) that encode the α2, α4 and β2 subunits of the neuronal nicotinic acetylcholine receptor.[@b5]--[@b7] More recently, mutations in the sodium-activated potassium channel KCNT1[@b8] were shown to cause a small number of severe familial and sporadic cases. Mutations in the mTOR signaling protein DEPDC5 may also present with NFLE, including in 13% of families in one study.[@b9]--[@b12] The etiology of other familial NFLEs remain to be elucidated, but additional genes are expected to be involved. Gain of function of mutated nicotinic cholinergic receptors appears to be the common mechanism in in vitro studies of human mutations.[@b5],[@b13] Based on this electrophysiological data, and the genetic data above, other proteins of the cholinergic nervous system may be involved in the pathogenesis of NFLE.

Herein we report a small Australian family of Italian origin segregating autosomal recessive NFLE (ARNFLE) and intellectual disability. Using a methodology we recently reported[@b14] we performed linkage analysis with whole exome sequencing data to map the disorder to multiple genomic loci, and then, using the same sequence data, we identified the causative gene mutation on chromosome 14. The mutated gene, *PRIMA1*, encodes a proline-rich transmembrane protein that efficiently transforms secreted acetylcholinesterase (AChE) into an enzyme anchored on the outer cell surface.

Materials and Methods
=====================

Family and sporadic cases
-------------------------

A two-generation Australian family of Italian origin with NFLE and intellectual disability was studied (Fig.[1](#fig01){ref-type="fig"}). The Human Research Ethics Committee of Austin Health, Melbourne, Australia, approved this study. Informed consent was obtained from living subjects or their relatives. For re-sequencing experiments, 300 sporadic patients diagnosed with NFLE were collected and phenotyped including 212 cases with Italian ancestry.

![Pedigree of Australian family. Two-generation Australian family of Italian origin segregating ARNFLE (autosomal recessive nocturnal frontal lobe epilepsy) and intellectual disability showing genotypes of the *PRIMA1* c.93+2 nucleotide. Open symbols unaffected; shaded symbols affected; double line consanguineous event; diagonal line deceased. A breast tissue sample was available from individual I:2 for genotyping by Sanger sequencing; blood samples were obtained from the other family members (I:1, II-1, II-2 and II-3), and these samples were exome sequenced.](acn30002-0821-f1){#fig01}

Patient samples
---------------

Whole blood was obtained and genomic DNA extracted using a Qiagen QIAamp DNA Maxi Kit (Valencia, CA). For individual I:2, who died of breast cancer, paraffin-embedded breast tissue was available for genotyping. The paraffin was removed by treatment with xylene and DNA extracted using phenol chloroform as described previously.[@b15] Fresh whole blood samples were obtained from affected individual II:3 and her unaffected brother II:1 to generate a lymphoblastoid cell line (LCL) for transcript studies.

Whole exome sequencing
----------------------

Exome sequencing was performed using 3 *μ*g of venous blood-derived genomic DNA from each of four family members (I:1, II-1, II-2 and II-3; Fig.[1](#fig01){ref-type="fig"}). Genomic DNA was sonicated to approximately 200 base pair (bp) fragments and adaptor-ligated to make a library for paired-end sequencing. Following amplification and barcoding, the libraries were hybridized to biotinylated complementary RNA oligonucleotide baits from the SureSelect Human All Exon 50 Mb Kit (Agilent Technologies, Santa Clara, CA) and purified using streptavidin-bound magnetic beads as described previously.[@b16] Amplification was conducted prior to sequencing on the Illumina HiSeq 2000 system (San Diego, CA). The exome design covers 50 megabases of human genome that includes all exons annotated in the GENCODE project (reference annotation for the ENCODE project; Wellcome Trust Sanger Institute) and consensus CDS database (CCDS -- March 2009) as well as 10 bp of flanking sequence for each targeted region and small noncoding RNAs from miRBase (<http://www.mirbase.org/>) (v.13) and Rfam (<http://rfam.xfam.org/>).

Whole exome analysis and linkage mapping
----------------------------------------

Exome sequencing reads were aligned with Novoalign version 3.02.00 (<http://www.novocraft.com/>) to the human genome assembly with ambiguous SNPs (hg19 dbSNP132-masked, UCSC Genome Browser). PCR duplicates were removed using MarkDuplicates from Picard (<http://picard.sourceforge.net>).

For linkage analysis, a previously described method was used.[@b14] Briefly, genotypes of SNPs at HapMap Phase II loci[@b17],[@b18] were inferred using GATK UnifiedGenotyper[@b19],[@b20] with a required minimum depth of 10 reads per sample, to produce variant call format (VCF) files. LINKDATAGEN[@b17] produced files for linkage, including removing Mendelian errors. To satisfy linkage equilibrium assumptions markers were chosen so that they were approximately 0.3 cM apart when available. Inbreeding coefficients (*F*) were estimated using the FEstim[@b21] algorithm. The estimated inbreeding coefficients were used to generate an appropriate pedigree with an inbreeding loop (Fig.[1](#fig01){ref-type="fig"}) for homozygosity mapping. Multipoint parametric linkage analysis using exome genotypes was performed using MERLIN[@b22] with a fully penetrant recessive disease model with disease allele frequency 0.00001, with the pedigree described in Figure[1](#fig01){ref-type="fig"} for homozygosity mapping, and the nuclear family for recessive disease model mapping.

Variant detection was performed with GATK HaplotypeCaller and variant annotation using ANNOVAR.[@b23] Exome variants were filtered and selected according to the following criteria for the homozygous and compound heterozygous recessive models: location within a linkage region, genotypes fitting the disease model, a minor allele frequency ≤0.01 (0.05) in the exome variant server dataset (<http://evs.gs.washington.edu/EVS/>) and 1000 Genomes,[@b24] a minor allele frequency of ≤0.05 in the Exome Aggregation Consortium database, appearance in \<10 alleles of our in-house exome dataset, and mutation type (missense, nonsense, coding indel or splice site variant). Compound heterozygous variants were filtered at the gene level, where candidate genes had to have at least two remaining variants after filtering. Variants in the same gene were assessed pairwise requiring that exactly one variant was heterozygous in the father (I:1), no more than one variant was observed in the unaffected sibling (II:1), and not present in cis-phase as assessed in IGV,[@b25],[@b26] when possible.

PCR and sanger sequencing
-------------------------

The *PRIMA1* gene and exome variants were amplified using gene-specific primers (Table[1](#tbl1){ref-type="table"}) designed to the reference human gene transcripts (NCBI Gene; <http://www.ncbi.nlm.nih.gov/>). Amplification reactions were cycled using a standard protocol on a Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA) at 60°C annealing temperature for 1 min. Bidirectional sequencing of all exons and flanking regions was completed with a BigDye™ v3.1 Terminator Cycle Sequencing Kit (Applied Biosystems), according to the manufacturer's instructions. Sequencing products were resolved using an 3730× L DNA Analyzer (Applied Biosystems). All sequencing chromatograms were compared to published cDNA sequence; nucleotide changes were detected, using Codon Code Aligner (CodonCode Corporation, Dedham, MA).

###### 

Oligonucleotides used in this study

  Target                           Oligonucleotide (5′-3′)
  -------------------------------- -----------------------------------
  *PRIMA1* exon 1                  CTGACCCTAGCCTTGCTCTC (forward)
  AGGAGGGAAGGGACAGCT (reverse)     
  *PRIMA1* exon 2                  CAGCTTCTAGTTGCCTTATGGTC (forward)
  CTCAGTGGATCTTCGTGGG (reverse)    
  *PRIMA1* exon 3                  CATGACCAGCTCATCCAGG (forward)
  ATGTGTGTAGGAGCCCCAA (reverse)    
  *PRIMA1* exon 4                  ACTAATGGTGTCCCTGCCTC (forward)
  ACCTGCTTTCCCATGTCCAC (reverse)   

Generation and analysis of lymphoblastoid cells
-----------------------------------------------

Immortalized lymphoblastoid cell lines were established from venous blood of family members II:1 and II:3 using Epstein--Barr virus and maintained in RPMI-1640 medium supplemented with 20% fetal calf serum. RNA was extracted from the cells using an RNeasy Minikit (Qiagen) and cDNA generated using a SuperScript III First-Strand Synthesis System (LifeTechnologies, Grand Island, NY) according to the manufacturer's instructions. PCR was performed as described above using oligonucleotides designed to *PRIMA1* mRNA and products were resolved on 2% agarose gels.

Minigene assay
--------------

Minigenes were generated using Exontrap vector (MoBiTec Molecular Biotechnology, Goettingen, Germany), which includes a 5′ and a 3′ exon separated by a 600 bp intron containing a polylinker for cloning of DNA of interest. Wild-type and mutant (c.93+2T\>C) *PRIMA1* fragments were amplified from genomic DNA of family members II:1 and II:3, respectively, using PCR with the primers 5′-AGGCTTGGTTTACTAGGGTG (forward) and 5′-GAGAACCA**ACTAGT**GGGGTGGCTGCAAGA (reverse, introduced SpeI site is highlighted in bold). The PCR products were digested with XmaI (restriction site is located in intron 1--2) and SpeI, and cloned into XmaI/SpeI-digested polylinker of Exontrap vector. The resulting minigenes contained 307 bp fragment of *PRIMA1*: exon 2 (124 bp) with flanking intronic sequences (83 bp of intron 1--2 and 100 bp of intron 2--3). The minigene sequences were confirmed by Sanger sequencing.

HEK293T cells (a human embryonic kidney cell line stably transfected with the SV40 large T antigen) were maintained in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 *μ*g/mL streptomycin, and 2 mmol/L glutamine. The cells were transfected with wild-type or mutant *PRIMA1* minigenes, or empty Exontrap vector, using Lipofectamine-2000™ (Invitrogen). Twenty-four or 48 h post-transfection the cells were harvested and total RNA was extracted using an RNeasy Minikit (Qiagen). cDNA was generated from 1 *μ*g of total RNA using SuperScript III reverse transcriptase and random hexamer primers (Invitrogen). PCR was performed on the cDNA using Platinum High Fidelity Taq (Invitrogen) with the primers binding to the 5′ and 3′ exons of Exontrap vector. The resulting PCR products were analyzed by electrophoresis on a 2% agarose gel.

Results
=======

Clinical details
----------------

Two of three siblings with unaffected parents, who were born in the same small Italian village, were diagnosed with NFLE and intellectual disability (Fig.[1](#fig01){ref-type="fig"}). Both required long-term institutional care. The 53 year-old female proband (II:3) had a history of motor and speech delay, short stature, ataxic gait, congenital nystagmus, and a squint. Chromosome analysis, metabolic screening and computed tomography (CT) were normal in childhood. During early childhood she developed seizures that persisted throughout adult life. The predominant attacks were nocturnal hyperkinetic seizures with duration ∼1--2 min and a frequency of 1--2 per week characterized by loud vocalizations, bilateral asymmetrical limb movements, often with incontinence and postictal confusion. Occasional generalized convulsions also occurred. Examination revealed nystagmus, moderate intellectual disability, and a broad-based gait without other specific cerebellar signs. Video electrocephalogram (EEG) confirmed frontal lobe nocturnal hyperkinetic attacks, and diurnal staring attacks thought to be behavioral. CT scans and MRI brain showed no specific lesions; there was a suggestion of mild cerebellar atrophy. Her clinical course was relatively stable over the last two decades.

Her 61-year-old affected brother (II:2) shares many clinical features with his sister. He had congenital nystagmus and developed epilepsy in early childhood characterized by monthly ∼1--2-min nocturnal seizures with vocalization, asymmetrical limb movements and postictal drowsiness as well as brief generalized tonic-clonic seizures in the early morning or late evening. Clinical evaluation revealed moderate intellectual disability, nystagmus, and a mild-ataxic gait. EEG showed slow, poorly sustained posterior dominant rhythm, delta slowing, with bifrontal epileptiform discharges. Brain CT revealed mild cerebral and cerebellar atrophy. He required a number of hospitalizations for poor seizure control.

Candidate gene screening
------------------------

The coding regions and splice sites of three known ADNFLE genes -- *CHRNA2*, *CHRNA4*, and *CHRNB2* -- were Sanger sequenced without identification of a causal mutation. The *KCNT1* and *DEPDC5* genes were discovered to be causal NFLE genes only after this study commenced and no mutation of these genes was found in the subsequent exome sequencing analysis.

Linkage mapping using exome data detects multiple genomic loci
--------------------------------------------------------------

The inheritance pattern in the family was unclear although a recessive mode appeared most likely. We performed linkage analysis with a fully penetrant recessive model using 7102 SNP markers generated from the exomes of four family members (I:1, II:1, II:2 and II:3; Fig.[1](#fig01){ref-type="fig"}). We tested the hypothesis that the family was consanguineous and FEstim analysis indicated that the parents were related (*F* estimates 0.034, 0.021, 0.036 (SE 0.010, 0.009, 0.014) for II:1, II:2, and II:3, respectively), with an inferred relationship of second-cousins. The father (I:1) also showed evidence of consanguinity (*F* = 0.022 \[SE 0.009\]), but his inbreeding loop is not relevant to the detection of autozygosity for this phenotype. Multipoint parametric linkage analysis using a pedigree with an inferred inbreeding loop revealed multiple linkage peaks including four with a parametric LOD score \>1.5 (Fig.[2A](#fig02){ref-type="fig"}; Table[2](#tbl2){ref-type="table"}), and using the nuclear pedigree produced 36 regions with LOD score \>0.5 (Fig.[2B](#fig02){ref-type="fig"}; Table[3](#tbl3){ref-type="table"}), allowing us to exclude 98 and 74% of the autosome, respectively.

![Whole exome sequencing and linkage mapping. (A) Genome-wide parametric LOD scores generated using exome data assuming an autosomal recessive inheritance model with consanguinity. Multiple linkage peaks were detected with the highest LOD score of ∼1.93 detected for regions on chromosomes 8 and 14. (B) Genome-wide parametric LOD scores generated using exome data assuming an autosomal recessive inheritance model with the nuclear pedigree. Multiple linkage peaks were detected with the highest LOD score of ∼0.71. (C) Representative sequence chromatograms of c.93+2 genotypes in the family -- the results for three individuals are shown.](acn30002-0821-f2){#fig02}

###### 

Chromosomal regions with LOD \> 1.5 identified by homozygosity mapping

  Chr   Flanking genetic markers                                                             
  ----- -------------------------- ------------- -------- ----------- ------------- -------- --------
  7     rs17241389                 83,764,309    101.32   rs2106432   92,970,847    107.25   1.8970
  8     rs3935174                  131,165,086   144.37   rs2292781   141,559,358   161.5    1.9264
  13    rs7997193                  56,574,363    55.7     rs9541675   69,559,370    63.66    1.5088
  14    rs3818263                  92,588,002    90.12    rs1047351   99,876,505    106.71   1.9263

chr, chromosome; cM, centimorgan.

###### 

Chromosomal regions with LOD \> 0.5 identified by recessive disease model mapping

  Chr   Flanking genetic markers                                                                
  ----- -------------------------- ------------- --------- ------------ ------------- --------- --------
  1     rs12127966                 4,234,940     9.937     rs6689940    6,281,090     15.914    0.7084
  1     rs2803155                  77,958,837    106.42    rs541628     117,256,763   147.404   0.7085
  1     rs11264818                 157,742,017   168.503   rs10800465   162,310,313   175.048   0.7085
  2     rs6716306                  102,014,754   120.716   rs13427053   105,186,053   123.054   0.7083
  2     rs13020764                 125,664,440   144.186   rs4525749    139,069,573   157.912   0.7085
  2     rs6436746                  228,893,467   242.144   rs10169296   236,766,825   256.37    0.7085
  3     rs2674533                  651,876       0.799     rs1562080    4,025,703     10.174    0.7083
  3     rs9873219                  77,354,463    104.709   rs9873303    115,396,528   125.341   0.7085
  3     rs7633364                  185,218,549   196.279   rs2280268    193,031,926   213.549   0.7085
  6     rs9448707                  80,139,318    88.977    rs9391249    105,343,433   108.871   0.7085
  7     rs1429745                  85,005,512    101.86    rs4727629    105,467,529   118.864   0.7085
  8     rs17745485                 417,836       0.383     rs5020778    13,596,612    30.377    0.7084
  8     rs7836437                  70,840,655    87.368    rs10098671   87,243,097    100.132   0.7085
  8     rs7830253                  108,185,786   119.456   rs16899173   124,995,902   133.622   0.7084
  8     rs13278110                 131,097,405   144.368   rs11167136   143,310,815   164.929   0.7085
  9     rs4237150                  4,290,085     11.461    rs4741080    11,009,202    25.175    0.7085
  9     rs3824372                  17,752,252    36.778    rs17781724   24,538,114    46.728    0.7085
  9     rs7850371                  28,164,681    53.241    rs12238895   80,827,249    78.289    0.7085
  9     rs10988451                 101,741,666   103.679   rs4240435    132,385,003   142.573   0.7085
  10    rs1769236                  734,229       0.192     rs4749890    9,739,317     21.719    0.7085
  10    rs17685697                 28,620,873    51.218    rs1961333    45,612,064    64.193    0.7079
  10    rs1547843                  91,738,263    117.5     rs4463806    115,597,993   140.176   0.7085
  11    rs325606                   6,243,982     12.483    rs9787738    11,161,897    20.532    0.7085
  11    rs17609863                 29,293,934    46.016    rs11601550   133,707,109   155.667   0.7085
  12    rs4765268                  126,133,693   151.605   rs12300232   133,648,090   174.669   0.7085
  14    rs1984536                  26,637,188    18.918    rs11623717   54,414,132    48.798    0.7085
  14    rs7150314                  82,384,079    77.741    rs4448834    107,170,398   120.134   0.7085
  15    rs453151                   70,097,675    86.294    rs3743475    89,172,558    105.572   0.7085
  16    rs7359494                  310,574       0.172     rs3748980    12,875,075    29.646    0.7085
  16    rs11643526                 61,668,000    80.826    rs8044379    76,274,993    94.041    0.7085
  17    rs11651333                 11,858,949    30.461    rs11656692   31,327,572    50.541    0.7085
  17    rs4128941                  63,531,331    89.185    rs7211813    68,144,014    96.289    0.7085
  18    rs2293517                  10,784,331    32.578    rs11662426   36,920,736    56.684    0.7085
  18    rs5375                     74,962,810    111.193   rs9950415    77,643,034    117.589   0.5693
  19    rs11881257                 54,196,217    93.877    rs12691095   56,718,895    103.318   0.7085
  21    rs9981410                  17,450,982    5.82      rs1005164    45,680,103    58.637    0.7085

chr, chromosome; cM, centimorgan.

Exome variant analysis reveals a mutation in the *PRIMA1* gene
--------------------------------------------------------------

We generated high coverage exomes for all four family members (Table[4](#tbl4){ref-type="table"}). Exome variants under the linkage peaks were filtered as described in the Methods section where one homozygous recessive and twelve compound heterozygous variants in one and six genes, respectively, were identified that passed filtering (Tables[5](#tbl5){ref-type="table"}, [6](#tbl6){ref-type="table"}). The homozygous variant on chromosome 14 in the *PRIMA1* gene is a novel splice site mutation (c.93+2T\>C) that substitutes the invariant 'T' allele[@b27] of the 5′ splice site of the intron following exon 2 (the first coding exon) for a 'C' (Fig.[2C](#fig02){ref-type="fig"}). This mutation is predicted to cause skipping of exon 2 during *PRIMA1* pre-mRNA splicing as supported by splice prediction software (Analzyer Splice Site Tool, Tel Aviv University, Israel) indicating the splicing machinery will fail to recognize the mutant splice site. Since individual I:2 was not exome sequenced, her c.93+2 genotype was determined by Sanger sequencing of genomic DNA derived from her breast tissue (Fig.[1](#fig01){ref-type="fig"}). Although *PRIMA1* lymphocyte expression was not reported in publicly available expression databases, we obtained a fresh blood sample from affected (II:3) and unaffected (II:1) sibs and generated lymphoblastoid cell lines (LCLs) to check for mRNA expression. However, *PRIMA1* expression was not detected in cell lines from either family member (data not shown).

###### 

Exome coverage statistics

  Patient   Total reads   Mean read depth   \% bases covered by 2 reads   \% bases covered by 5 reads   \% bases covered by 10 reads
  --------- ------------- ----------------- ----------------------------- ----------------------------- ------------------------------
  I:1       2278520917    44                94                            91                            85
  II:1      3801912357    73                96                            94                            91
  II:2      1802808122    35                94                            89                            81
  II:3      5292190911    102               96                            94                            92

###### 

Filtered homozygous recessive exome variants under linkage peaks

  Chr   Genomic site   Variant   Gene       Amino acid   Effect
  ----- -------------- --------- ---------- ------------ -------------
  14    94,253,970     T\>C      *PRIMA1*   --           Splice site

###### 

Filtered compound heterozygous exome variants under linkage peaks

  Chr   Genomic site   Variant                 Gene        Amino acid   Effect
  ----- -------------- ----------------------- ----------- ------------ -------------------------
  11    6,519,561      A\>G                    DNHD1       Q\>R         Nonsynonymous SNV
  11    6,568,866      C\>T                    DNHD1       R\>C         Nonsynonymous SNV
  11    48,997,336     C\>T                    LOC120824   C\>Y         Nonsynonymous SNV
  11    49,003,195     C\>A                    LOC120824   C\>F         Nonsynonymous SNV
  16    4,934,157      -\>CCACCTTCTCCTTGACCT   PPL         V\>EVKEKVV   Nonframeshift insertion
  16    4,945,400      CTC\>-                  PPL         E\>-         Nonframeshift deletion
  16    11,097,073     G\>C                    CLEC16A     G\>A         Nonsynonymous SNV
  16    11,272,419     C\>A                    CLEC16A     P\>T         Nonsynonymous SNV
  17    18,129,027     G\>A                    LLGL1       A\>T         Nonsynonymous SNV
  17    18,133,277     A\>C                    LLGL1       N\>T         Nonsynonymous SNV
  17    66,879,927     C\>T                    ABCA8       --           Splice site
  17    66,914,289     G\>C                    ABCA8       P\>R         Nonsynonymous SNV

None of the six genes containing compound heterozygous variants (Table[6](#tbl6){ref-type="table"}) are convincing candidates. For *LOC120824*, nothing is known while little functional information is available for *DNHD1,* other than it encodes the dynein heavy chain domain 1 that is predicted to be a chaperone or mitotic protein,[@b28] and *CLEC16A*, other than it is a susceptibility gene for diabetes, multiple sclerosis, and immunoglobulin A deficiency.[@b29] *ABCA8* is a xenobiotic transporter gene of the ABC subfamily that transport foreign chemicals, such as antibiotics, across cellular membranes by ATP hydrolysis.[@b30] *PPL* encodes periplakin that is expressed in brain but its known function is to associate with desmosomal plaques and keratin filaments in the epidermis, and mice null for the gene are phenotypically normal.[@b31] A tumor suppressor gene, *LLGL1* regulates basal protein targeting in both embryonic and larval Drosophila neuroblasts,[@b32] and newborn homozyous knockout Lgl1 pups develop severe hydrocephalus and die neonatally.[@b33]

Confirmation of *PRIMA1* exon skipping in vitro
-----------------------------------------------

Since *PRIMA1* was not expressed in lymphocytes and we did not have access to other tissues from family members, we examined the effect of the mutation using a minigene assay. *PRIMA1* DNA fragments containing exon 2 (124 bp) with flanking intronic sequences (wild-type and c.93+2T\>C) were amplified from the genomic DNA of unaffected and affected family members, respectively, and cloned into a splicing-competent minigene vector. HEK293T cells were transfected with the minigenes and the vector, and incubated for 24 or 48 h. Cellular RNA was then extracted and the splicing of minigene-derived RNA was analyzed by RT-PCR using PCR primers binding to the 5′ and 3′ exons of the vector. The results revealed incorporation of exon 2 in RNA produced by the wild-type minigene and skipping of exon 2 in RNA produced by the mutant minigene (Fig.[3](#fig03){ref-type="fig"}).

![Minigene analysis reveals exon skipping. (A) RT-PCR results showing skipping of the first coding exon of *PRIMA1* due to the c.93+2T\>C mutation 48 h following transfection into HEK293T cells. A 100 base pair marker (lane 1) was run. The 124 base pair first exon of *PRIMA1* is only expressed from the wild-type minigene construct (lane 2), resulting in a 369 base pair product. Whereas the mutant (lane 3) and empty vector control (lane 4) both lack the first exon producing 245 base pair products. The same result was observed in cells harvested 24 h posttransfection (data not shown). (B) Schematic illustration of exon skipping caused by the c.93+2T\>C mutation compared to the wild-type splicing.](acn30002-0821-f3){#fig03}

Re-sequencing of *PRIMA1* in additional cases
---------------------------------------------

We designed oligonucleotides (Table[1](#tbl1){ref-type="table"}) to screen the entire coding region and splice sites of the *PRIMA1* gene. Three hundred unrelated patients diagnosed with NFLE, including 212 with Italian ancestry, were screened using these oligonucleotides by Sanger sequencing or as part of the exome sequencing studies. No potential recessive or compound heterozygous mutations were detected.

Discussion
==========

Nocturnal frontal lobe epilepsy is an important epilepsy syndrome known to be inherited in an autosomal dominant manner or to occur sporadically. Recessive inheritance has not been previously recognized. Using a whole exome and linkage analysis strategy, we discovered the cause for ARNFLE and intellectual disability in this family, being a mutation in the *PRIMA1* gene.

Acetylcholinesterase (AChE) plays a pivotal role as a hydrolase in the central and peripheral nervous systems catalyzing the hydrolysis of acetylcholine (ACh) to maintain neurotransmitter homeostasis. Inhibition of AChE leads to enhanced cholinergic responses due to excess ACh over-stimulating nicotinic and muscarinic receptors.[@b34] This can alter both central and peripheral processes, including control of respiration and seizure activity, autonomic, and somatic motor functions. In brain, AChE is found in its functional form as a tetramer associated with PRIMA1 at neuronal synapses. This association is facilitated by interaction between the tryptophan amphiphilic tetramerization domains on the catalytic subunits of AChE and the proline-rich attachment domain (PRAD) on the extracellular domain of PRIMA1.[@b35]

Perturbation of the cholinergic system has been linked to the pathogenesis of ADNFLE, specifically the increased sensitivity of nicotinic acetylcholine receptor (nAChR) subunits to ACh. Dominant mutations in three receptor subunits have been found in families segregating NFLE.[@b5]--[@b7] This hypersensitivity was demonstrated for the α2 subunit mutation in vitro by whole-cell recordings of HEK293 cells transfected with wild-type or mutant receptor.[@b5] Loss of PRIMA1 represents a new mechanism for over-stimulation of nAChRs via reduction in AChE activity leading to accumulation of ACh. A severe reduction in AChE has already been demonstrated in PRiMA knock-out mice that lack the critical PRAD domain.[@b34] In the striatum, chosen because it contains the highest level of AChE in the brain, PRiMA knockout mice only exhibit 2--3% of wild-type AChE activity despite having normal *AChE* mRNA levels. The residual AChE is localized to the endoplasmic reticulum. These data indicate that PRiMA is critical to intracellular processing of AChE, and targeting it to and stabilizing it at the axon. It is noteworthy that PRiMA is only required to anchor AChE at synaptic junctions in the brain, and not in the muscle, consistent with the phenotype observed in the family studied here.

The splice site mutation we found in *PRIMA1* results in skipping of the first coding exon that contains the first 93 base pairs of coding sequence. While in-frame, this would result in loss of the first 31 amino acids of the PRIMA1 protein, including the methionine start site and most of the signal peptide. An alternative methionine start site is not present until position 137, close to the C-terminus of the 153 amino acid PRIMA1 protein. Since the affected siblings are homozygous for the mutation, the effect is predicted to be a complete knockout of PRIMA1 in their cells.

We describe ARNFLE, and document a more severe phenotype than usually observed in dominant cases that includes intellectual disability. Our genetic analysis reveals the first cause for this disease being mutation of *PRIMA1*. Whilst it would have been ideal to identify further independent subjects with mutated *PRIMA1*, analysis of 300 other unrelated cases was negative. However, the likely loss of function of PRIMA1 caused by this mutation and its biological plausibility because of its effect on the cholinergic system strongly suggest it is a novel, albeit rare, cause of NFLE. This further highlights the role of the cholinergic system in this characteristic nocturnal epilepsy syndrome.
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